Bio-Rad’s iQ-Check Vibrio Real-Time PCR Kit Receives AOAC INTERNATIONAL Validation

Date: 
06/25/2020
iQ-Check Vibrio Real-Time PCR Kit Receives AOAC INTERNATIONAL Validation
AOAC INTERNATIONAL recently granted validation for Bio-Rad’s iQ-Check Vibrio Real-Time PCR Kit.

The Kit Can Be Used to Detect the Presence of the Three Main Vibrio Species that May Be Found in Raw and Undercooked Seafood

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that AOAC INTERNATIONAL has validated Bio-Rad’s iQ-Check Vibrio Real-Time PCR Kit to detect the presence of the three main Vibrio species found in raw or undercooked seafood (V. cholerae, V. parahaemolyticus, and V. vulnificus) with an enrichment time that is faster than other existing testing methods.

To obtain this approval through the AOAC INTERNATIONAL’s Performance Tested Methods program, a validation study was performed that demonstrated no significant differences between the iQ-Check Vibrio Real-Time PCR Kit method and the U.S. Food and Drug Administration’s Bacteriological Analytical Manual “Chapter 9 Vibrio” (May 2004) reference method, even with the shortened enrichment time offered by Bio-Rad’s method. The assay was validated for use with 125-gram test portions of cooked shrimp as well as 25-gram portions of cooked and raw shrimp, raw mussels, raw oysters, and raw tuna. The iQ-Check Free DNA Removal Solution, which removes problematic free DNA from the sample with a nontoxic and easy-to-use procedure, was also validated for all of the sample types.

The iQ-Check Vibrio Real-Time PCR Kit method was approved for use with the Bio-Rad Vibrio Enrichment Broth (after a 7- to 9-hour enrichment period) and alkaline phosphate water (after a 6- to 18-hour enrichment period).

For further information about the iQ-Check Vibrio Real-Time PCR Kit, please visit bio-rad.com/vibrio.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. IQ-CHECK is a trademark of Bio-Rad Europe GmbH.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration, severity and impact of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain issues, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer
520-741-5653
wendy_lauer@bio-rad.com

CG Life
Alyssa Salela
630-935-6369
asalela@cglife.com